Arca
Skip to content
Tools
Tools

Warning Letter to ARJ Infusion Services Inc

Unspecified. See ARJ Infusion Services's company page or this site's inspections.

On Mar 6, 2019, FDA's CDER sent ARJ Infusion Services Inc a warning letter.

  • Letter date: Mar 6, 2019
  • Issued by: CDER
  • Closeout: โ€”

The Letter

As posted on FDA.gov โ†—; cited 21 CFR sections link to their page.

Dear Ms. Sackuvich:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firmโ€™s corrective actions in response to our warning letter (ref: Case# 548673) dated April 2, 2018. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDAโ€™s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely, /S/ Nicholas F. Lyons Compliance Director Division of Pharmaceutical Quality Operations III

Record

Recipient
Mary L. Sackuvich
FDA site ID (FEI)
3013452490
Cited
โ€”

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.